Dermatologic Therapy最新文献

{"title":"Clinical Evaluation of a 200-kDa Auto-Crosslinked Hyaluronic Acid Injectable in Facial Skin Quality: A Prospective Pilot Observational Study","authors":"Andrea Lazzarotto, Salvatore Piero Fundarò, Serena Gioana, Patrizia Piersini, Ilaria Proietti, Alberto Passi","doi":"10.1155/dth/5512277","DOIUrl":"https://doi.org/10.1155/dth/5512277","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that plays a fundamental role in maintaining dermal hydration, elasticity, and turgor through its ability to retain large amounts of water and regulate the extracellular matrix (ECM). With advancing age, oxidative stress, ultraviolet exposure, and enzymatic degradation contribute to fragmentation and depolymerization of HA, resulting in loss of firmness, elasticity, and dermal density. Recent progress in biomaterial science has led to the development of HA with auto-crosslinked polymer (ACP) technology. This process creates a chemically crosslinked three-dimensional polymeric network without chemical residues, allowing the gradual release of bioactive 200-kDa low-molecular-weight HA fragments hypothesized to support fibroblast stimulation and collagen synthesis, based on preclinical evidence. This mechanism is hypothesized to support regenerative effects beyond simple volumetric correction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate, in a pilot uncontrolled observational setting, physician-rated clinical outcomes following intradermal treatment with low-molecular-weight HA (200 kDa) stabilized with ACP technology in women with mild-to-moderate facial aging. No control group, placebo arm, objective biophysical measurements, or independent blinded evaluation were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Thirty healthy female patients underwent a minimum of three treatment sessions spaced 4 weeks apart (individual session counts are reported in Table 1) using a standardized vector injection technique (three vector technique) aligned with facial tension lines. Patients were initially classified according to aging severity using the Bazin Cheek Fold Score. Clinical outcomes were subsequently evaluated using the Global Aesthetic Improvement Scale (GAIS) and the Global Improvement Clinical Scale (GICS), which were applied exclusively after completion of the full treatment protocol to document physician-rated post-treatment scores. Statistical analyses included descriptive statistics, Welch’s <i>t</i>-test, Hedges’ g for intergroup effect size, and Pearson’s correlation coefficient for exploratory analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Posttreatment physician-rated assessments documented improvements in skin appearance across both aging groups. In the low-grade group, median posttreatment GAIS was 2 (range 1–3); in the high-grade group, median GAIS was 2 (range 1–4). Median GICS was 1 (range 1-2) in both ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5512277","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shilajit Mouthwash as an Adjunct to Corticosteroid Therapy for Oral Lichen Planus: A Randomized Clinical Trial","authors":"Aylar Afshari,&nbsp;Shohreh Alipour,&nbsp;Fahimeh Rezazadeh,&nbsp;Fatemeh Lavaee,&nbsp;Maryam Shahrokhi Sardoo","doi":"10.1155/dth/7960748","DOIUrl":"https://doi.org/10.1155/dth/7960748","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Oral lichen planus (OLP) is a chronic inflammatory condition primarily managed with corticosteroids, which carry significant side effects. Shilajit, a traditional herbal–mineral remedy with anti-inflammatory and ulcer-healing properties, may offer an adjunct therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Experimental Procedure</h3>\u0000 \u0000 <p>This randomized, single-blind, placebo-controlled trial evaluated shilajit mouthwash in 51 OLP lesions (27 intervention, 24 control) alongside standard corticosteroid and nystatin therapy. Pain (visual analog scale, VAS), lesion severity (Thongprasom score), and lesion size were assessed over 60 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Conclusion</h3>\u0000 \u0000 <p>Both groups showed reduced pain and lesion severity, but the shilajit group exhibited a more sustained reduction in Thongprasom scores (<i>p</i> = 0.02). Lesion size reduction was not significantly different between groups, except for between Days 30 and 60. In this pilot study, shilajit mouthwash showed a more sustained reduction in Thongprasom-based lesion severity than corticosteroid alone, with minimal side effects; however, pain and lesion size reduction did not differ significantly between groups, and the Thongprasom finding should be interpreted cautiously given a baseline imbalance between groups. Larger trials with balanced baseline severity are needed before shilajit’s efficacy as an adjunct OLP treatment can be confirmed.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Iranian Registry of Clinical Trials: IRCT20120101008585N9</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7960748","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Prospective Single-Arm Cohort Study on the Dynamic Attenuation of Therapeutic Effect of 308-nm Excimer Laser in the Treatment of Vitiligo Based on a Mixed-Effects Model and Time-Series Analysis","authors":"Yujin Sun,&nbsp;Shuxian Guo,&nbsp;Xuming Wang,&nbsp;Shuying Chang,&nbsp;Miao Miao,&nbsp;Guan Jiang","doi":"10.1155/dth/1873412","DOIUrl":"https://doi.org/10.1155/dth/1873412","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The purpose of this study was to investigate the attenuation of therapeutic efficacy of the 308-nm excimer laser in the treatment of vitiligo and to explore its temporal dynamics and underlying mechanisms through a mixed-effects model and time-series analysis, thereby providing a scientific basis for individualized treatment regimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design, Setting, and Participants</h3>\u0000 \u0000 <p>This was a multicenter, prospective cohort study comprising 170 patients with clinically stable vitiligo diagnosed between March and December 2024 at multiple participating dermatology clinics. Patients received 308-nm excimer laser therapy twice weekly. The Vitiligo Area Scoring Index (VASI) scores and repigmentation areas were recorded at baseline and at 2-week intervals over a 24-week period. A mixed-effects model combined with time-series analysis was utilized to calculate clinical efficacy, evaluate influencing factors, and analyze the dynamic trends of the treatment response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the initial phase of treatment, VASI scores decreased progressively as treatment advanced. However, between Weeks 21 and 24, the rate of VASI score reduction slowed considerably, with some patients exhibiting a therapeutic plateau or late-phase fluctuation (<i>p</i> &lt; 0.001), suggesting possible attenuation of the laser’s therapeutic effect.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The therapeutic efficacy of the 308-nm excimer laser in treating vitiligo undergoes dynamic attenuation and reaches a therapeutic plateau when continuous treatment extends to approximately 21–24 weeks.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Clinical Trial Registry: ChiCTR2600132228</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1873412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Fusion for Acne Severity Assessment With Exploratory Landmark Prediction of a 12-Week Treatment Response: A Prospective Single-Center Cohort Study","authors":"Xing Hu,&nbsp;Xiang Zhang,&nbsp;Jindong Zhang,&nbsp;Zainul Amiruddin Zakaria","doi":"10.1155/dth/8579669","DOIUrl":"https://doi.org/10.1155/dth/8579669","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Acne is a common chronic inflammatory skin disease, and the subjectivity of severity assessment and uncertainty in short-term treatment-response prediction remain important clinical challenges. This study aimed to develop a multimodal fusion model integrating clinical features, radiomics features, deep learning image features, and attention-based fusion for acne severity assessment, with an exploratory leakage-free landmark prediction of a 12-week treatment response.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Materials and Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This prospective single-center cohort study enrolled 2186 patients with acne in the main cohort between January 2022 and January 2024. Of these, 2000 completed the 12-week follow-up and constituted the response-prediction cohort because the week-12 treatment-response outcome was available only for follow-up completers. The original fixed severity-development/test analysis was also constructed within the same 2000 completers to maintain one harmonized dual-task analytic dataset. However, week-12 follow-up is not intrinsically required for baseline severity assessment, and restriction of the severity analysis to completers may introduce attrition-related selection bias. Because the source-level baseline records of the 186 participants who did not complete follow-up could not be reliably retrieved and linked to the final analytic database, a valid post hoc attrition comparison and an all-enrolled baseline severity sensitivity analysis were not feasible. This limitation is now explicitly and prominently acknowledged in the Abstract, Methods, Results, Table note, Figure legend, and Discussion. A separately recruited single-center temporal validation cohort included 120 patients. Clinical data and standardized lesion images were collected at baseline and follow-up visits. Random forest, XGBoost, modified VGG16-based image feature extraction, and attention-based multimodal fusion were constructed for severity assessment. Fixed patient-level test-set reporting used one prediction per participant. To avoid temporal information leakage, a 12-week treatment-response prediction used cumulative landmark inputs available before the week-12 outcome: baseline-only, baseline plus week 4, and baseline plus week 4 and week 8. Baseline treatment modality was included as a prespecified categorical clinical covariate in treatment-adjusted response models, whereas week-12 compliance and week-12 features were excluded from prospective prediction inputs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 2186 enrolled participants, 2000 completed the 12-week follow-up (completion rate 91.5%). In the fixed patient-level held-ou","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8579669","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Baseline LDL Cholesterol and Week-16 Secukinumab Response in Moderate-to-Severe Plaque Psoriasis: A Retrospective Cohort Study","authors":"Lihong Chen,&nbsp;Qi Yang,&nbsp;Hailun Wang,&nbsp;Szeman Cheung,&nbsp;Li Zhang,&nbsp;Xing Zou,&nbsp;Jiancheng Zhou,&nbsp;Feng Xue,&nbsp;Jie Zheng,&nbsp;Xia Li","doi":"10.1155/dth/5218624","DOIUrl":"https://doi.org/10.1155/dth/5218624","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Psoriasis is a systemic inflammatory disease frequently accompanied by cardiometabolic comorbidities. Whether baseline lipid status influences clinical response to interleukin-17A blockade remains insufficiently defined.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the association between baseline low-density lipoprotein cholesterol (LDL) and week-16 clinical response to secukinumab in patients with moderate-to-severe plaque psoriasis and to describe outcomes under 150-mg and 300-mg dosing regimens in real-world practice.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We performed a single-center retrospective cohort study including 325 patients with moderate-to-severe plaque psoriasis who received secukinumab for at least 16 weeks.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;Patients received either 150 mg or 300 mg secukinumab at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. The primary outcome was achievement of at least 75% improvement in Psoriasis Area and Severity Index (PASI75) at week 16. Propensity score weighting was used to reduce baseline imbalance between dosing groups. The primary association was estimated using multivariable logistic regression with baseline LDL modeled continuously and adjustment for multiple factors. Missing LDL was evaluated using measured-versus-missing comparisons and multiple imputation as a sensitivity analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;After inverse probability weighting, baseline demographic and disease severity variables were generally balanced between dose groups, although residual imbalance in selected laboratory variables remained. Week-16 PASI75 response did not differ significantly between the 150-mg and 300-mg groups after adjustment, while early PASI90 response was more frequent in the 300-mg group and week-16 PASI100 response was more frequent in the 150-mg group. Baseline LDL was inversely associated with PASI75 response at week 16 (ORs per 1 mmol/L increase, 0.696, and 95% CI: 0.497–0.976), and further multiple imputation as a sensitivity analysis confirmed the adjusted OR was 0.718 (95% CI: 0.516–0.999, &lt;i&gt;p&lt;/i&gt; = 0.049). Patients with low LDL had a higher PASI75 response rate than those with high LDL (85.2% vs 66.7%). In the 300-mg subgroup, high LDL was associated with lower PASI75 and PASI90 response rates. Secukinumab reduced selected inflammatory and metabolic biomarkers, including CRP, ESR, SCC, glucose, and triglycerides, but LDL and HDL did not show significant improvement over 16 weeks.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5218624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP-1 Receptor Agonists and Tirzepatide","authors":"Sebastián Guerrero-López,&nbsp;Sara Cataño-Restrepo,&nbsp;Sofía Pérez-Lalinde,&nbsp;Daniela Chaparro-Reyes","doi":"10.1155/dth/5742100","DOIUrl":"https://doi.org/10.1155/dth/5742100","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide have moved rapidly from diabetes management into widespread obesity treatment, drawing growing interest in their dermatologic implications. Given the close relationship between obesity, insulin resistance, systemic inflammation, nutritional alterations, and cutaneous homeostasis, these agents may influence the skin through both beneficial and adverse mechanisms.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To review and critically evaluate the current literature regarding the dermatologic effects of GLP-1RAs and tirzepatide, with emphasis on differentiating direct pharmacologic effects, indirect weight loss–mediated effects via metabolic changes, and multifactorial and uncertain mechanisms.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A focused narrative review was conducted in accordance with the principles of the Scale for the Assessment of Narrative Review Articles (SANRA) using targeted searches in PubMed/MEDLINE, Scopus, and Embase through April 2026. Preference was given to systematic reviews, meta-analyses, randomized clinical trials, multicenter observational studies, translational mechanistic research, and pharmacovigilance reports. Selected case reports were incorporated when considered clinically relevant. Findings were analyzed according to study quality, biological plausibility, consistency among different evidence sources, and applicability to dermatologic practice.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among the potential beneficial dermatologic effects, psoriasis showed the most promising evidence, with meta-analytic studies reporting reductions in Psoriasis Area and Severity Index scores and achievement of PASI 75 in a proportion of patients. Hidradenitis suppurativa also showed improvement in several observational studies, including reductions in disease activity, pain, and flare frequency, although the independent contribution of weight loss and metabolic improvement remains difficult to separate. Additionally, experimental data suggest possible benefits in wound repair through anti-inflammatory and angiogenic modulation, but clinical evidence in dermatology is still scarce. Hair loss emerged as the most consistently reported adverse cutaneous event; pharmacovigilance analyses and pooled clinical trial data suggest an increased risk, most commonly compatible with telogen effluvium associated with rapid weight reduction and metabolic stress. Injection-site reactions and mild hypersensitivity phenomena are relatively frequent","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5742100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Guselkumab on Serum Uric Acid Levels in Patients With Psoriasis: A Retrospective Cohort Study","authors":"Chao Wu,&nbsp;Dian-Mo Li,&nbsp;Xin-Yuan Zhang,&nbsp;Dan Shu,&nbsp;Wen-Ming Wang,&nbsp;Hai-Meng Wang,&nbsp;Yi Zhao,&nbsp;Chun-Xia He,&nbsp;Hong-Zhong Jin","doi":"10.1155/dth/1440163","DOIUrl":"https://doi.org/10.1155/dth/1440163","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyperuricemia (HUA) is common in psoriasis, but the effect of selective interleukin (IL)-23 inhibition on serum uric acid (UA) is inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this two-center retrospective cohort, 228 adults with chronic plaque psoriasis received guselkumab for 52 weeks. The primary outcome was the change in UA (ΔUA). Secondary outcomes included HUA resolution, new-onset HUA, predictors of baseline HUA and HUA resolution, and the association of ΔUA with Psoriasis Area and Severity Index (PASI) response and change in high-sensitivity C-reactive protein (ΔhsCRP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, 92 patients (40.4%) had HUA. UA decreased in the overall cohort (median ΔUA −10.5 μmol/L; bootstrap 95% CI −19.0 to −3.0; <i>p</i> &lt; 0.001), with the largest reduction among baseline HUA patients (median −35.5 μmol/L; 95% CI −53.5 to −17.0), 32.6% of whom achieved HUA resolution; cohort HUA prevalence fell from 40.4% to 33.3% (McNemar <i>p</i> = 0.023). 10.3% of patients with normal baseline UA developed new-onset HUA. ΔUA correlated weakly with ΔhsCRP but not with PASI change. Male sex and higher BMI independently predicted baseline HUA; lower baseline total cholesterol and higher baseline PASI independently predicted HUA resolution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Guselkumab was associated with a statistically significant but modest UA reduction, which was largest in patients with HUA and was independent of skin clearance over 52 weeks, suggesting an ancillary metabolic effect of IL-23 inhibition that warrants prospective confirmation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1440163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149145864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Once-Daily Versus Twice-Daily 0.5% Finasteride Solution in Men With Androgenetic Alopecia: A Randomized, Assessor-Blinded Clinical Trial","authors":"Chantaluck Muennarong,&nbsp;Pintusorn Kungvalpivat,&nbsp;Salinee Rojhirunsakool,&nbsp;Saranya Khunkhet","doi":"10.1155/dth/4369454","DOIUrl":"https://doi.org/10.1155/dth/4369454","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Topical finasteride has been alternatively used to treat male androgenetic alopecia, with studies indicating that once-daily topical finasteride is not only effective but may be superior to twice-daily application in suppressing scalp dihydrotestosterone levels. However, comparative data on hair regrowth between once-daily and twice-daily dosing are still lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To compare the application frequency of topical finasteride and its clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This randomized, assessor-blinded clinical trial involved 60 men with androgenetic alopecia. Participants were randomly allocated to receive a 0.5% finasteride solution once or twice daily for 24 weeks. Main outcome measures included changes in hair density and diameter, global photographic assessment, and adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-eight men completed the study. Intention-to-treat and complete-case analyses produced consistent findings. At 24 weeks, both once-daily and twice-daily applications resulted in significant improvements in total hair counts, terminal hair counts, and hair diameter from baseline (all <i>p</i> &lt; 0.001). Twice-daily dosing was significantly superior to once-daily dosing for increasing total hair density, +29.7 versus +20.7 hairs/cm² (<i>p</i> = 0.002), whereas increases in terminal hair counts and hair diameter were similar between groups. Twice-daily dosing was associated with a higher rate of significant hair regrowth, 61% versus 40% (<i>p</i> = 0.149). However, higher incidences of mild local reactions were also observed with twice-daily dosing, 17% versus 7% (<i>p</i> = 0.427).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Both once-daily and twice-daily regimens of topical finasteride 0.5% for 24 weeks were effective and well-tolerated in men with androgenetic alopecia. Twice-daily application provides additional clinical benefits compared to once-daily use.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Thai Clinical Trials Registry (TCTR): TCTR20240816002</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4369454","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness Evaluation of Early Versus Late Treatment With Dupilumab in Children and Adolescent With Severe Atopic Dermatitis in France","authors":"Jean Tardu,&nbsp;Marine Sivignon,&nbsp;Olfa Doghri,&nbsp;Noémie Allali,&nbsp;Jules Tavi,&nbsp;Anne-Lise Vataire,&nbsp;Kerry Noonan,&nbsp;Stéphanie Mallet,&nbsp;Pierre Levy","doi":"10.1155/dth/3086312","DOIUrl":"https://doi.org/10.1155/dth/3086312","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atopic dermatitis (AD) affects the quality of life (QoL) of children and adolescents in various domains. Although the burden of AD on children’s QoL is well established, evidence on the cost-effectiveness of interventions in pediatric AD remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this economic analysis is to investigate the cost-effectiveness and clinical relevance of early versus late treatment of severe AD with dupilumab in addition to best supportive care (BSC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cost-effectiveness model was adapted to the French context to compare over a 12-year time horizon patients with severe AD treated from age 6 with dupilumab and BSC versus patients with severe AD treated from age 6 to 11 years with BSC who then initiate dupilumab from age 12. Clinical data were mainly derived from Phase 3 clinical trials, which evaluated the efficacy and safety of dupilumab in AD in children aged 6–11 and adolescents aged 12–17 years. Health-related QoL inputs and resource use were obtained from the real-world studies ECLAJUNIOR and ECLADO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The base case results showed a total gain of 1.26 quality-adjusted life-years (QALYs) with an incremental cost of €24,475 when comparing early versus late initiation of dupilumab. This resulted in an incremental cost-effectiveness ratio (ICER) of 19,482 €/QALY gained. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The analysis shows that dupilumab has a high probability of being cost-effective in children 6 years and older who are suffering from severe AD in France.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3086312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between HLA Allele and Drug Patch Test Result in Cutaneous Adverse Drug Reactions","authors":"Rujira Leetanaporn,&nbsp;Supharat Suvichapanich,&nbsp;Punna Kunhapan,&nbsp;Surakameth Mahasirimongkol,&nbsp;Supitchaya Thaiwat","doi":"10.1155/dth/2676401","DOIUrl":"https://doi.org/10.1155/dth/2676401","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Drug patch testing was affected by multiple influencing factors. HLA allele-associated drug allergy was mentioned as one factor influencing drug patch testing. We aimed to evaluate the correlation between drug patch test and HLA alleles in patients with cutaneous adverse drug reactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study enrolled 30 patients, who had drug patch testing, to evaluate HLA alleles. We compared HLA alleles between patients with positive and negative patch test results and between those with positive patch tests and the Thai general population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 30 patients, including 20 positive patch test patients and 10 negative-patch test patients, a distribution for males (50%) was observed, with a mean age of 55.4 ± 15.5. The most prevalent cutaneous drug reactions in patch test-positive patients were morbilliform drug eruption 8/20 (40.0%) and fixed drug eruption 7/20 (35.0%). NSAIDs and antibiotics were the dominant culprit drug groups. These groups account for 5/20 (25.0%) and 4/20 (20.0%) of patients, respectively. None of the HLA alleles was significantly identified in patients with positive patch test compared to patients with negative patch test. However, HLA-B^∗54:01 and HLA-C^∗07:01 were significantly associated with patients who had positive patch test results for NSAID-induced minor drug reactions when compared with the Thai general population (<i>p</i> ≤ 0.0001), with odds ratios of 34 and 10, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this small pilot study, HLA-B^∗54:01 and HLA-C^∗07:01 alleles showed a preliminary association with positive patch test results in patients with NSAID-induced minor drug reactions. We hypothesized that HLA alleles might influence the positive patch test reaction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2676401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}